Cargando…

Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients

BACKGROUND: Electronic monitoring (EM) is used increasingly to measure medication non-adherence. Unbiased EM assessment requires fulfillment of assumptions. The purpose of this study was to determine assumptions needed for internal and external validity of EM measurement. To test internal validity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Denhaerynck, Kris, Schäfer-Keller, Petra, Young, James, Steiger, Jürg, Bock, Andreas, De Geest, Sabina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275282/
https://www.ncbi.nlm.nih.gov/pubmed/18284675
http://dx.doi.org/10.1186/1471-2288-8-5
_version_ 1782151849477931008
author Denhaerynck, Kris
Schäfer-Keller, Petra
Young, James
Steiger, Jürg
Bock, Andreas
De Geest, Sabina
author_facet Denhaerynck, Kris
Schäfer-Keller, Petra
Young, James
Steiger, Jürg
Bock, Andreas
De Geest, Sabina
author_sort Denhaerynck, Kris
collection PubMed
description BACKGROUND: Electronic monitoring (EM) is used increasingly to measure medication non-adherence. Unbiased EM assessment requires fulfillment of assumptions. The purpose of this study was to determine assumptions needed for internal and external validity of EM measurement. To test internal validity, we examined if (1) EM equipment functioned correctly, (2) if all EM bottle openings corresponded to actual drug intake, and (3) if EM did not influence a patient's normal adherence behavior. To assess external validity, we examined if there were indications that using EM affected the sample representativeness. METHODS: We used data from the Supporting Medication Adherence in Renal Transplantation (SMART) study, which included 250 adult renal transplant patients whose adherence to immunosuppressive drugs was measured during 3 months with the Medication Event Monitoring System (MEMS). Internal validity was determined by assessing the prevalence of nonfunctioning EM systems, the prevalence of patient-reported discrepancies between cap openings and actual intakes (using contemporaneous notes and interview at the end of the study), and by exploring whether adherence was initially uncharacteristically high and decreased over time (an indication of a possible EM intervention effect). Sample representativeness was examined by screening for differences between participants and non-participants or drop outs on non-adherence. RESULTS: Our analysis revealed that some assumptions were not fulfilled: 1) one cap malfunctioned (0.4%), 2) self-reported mismatches between bottle openings and actual drug intake occurred in 62% of the patients (n = 155), and 3) adherence decreased over the first 5 weeks of the monitoring, indicating that EM had a waning intervention effect. CONCLUSION: The validity assumptions presented in this article should be checked in future studies using EM as a measure of medication non-adherence.
format Text
id pubmed-2275282
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22752822008-03-26 Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients Denhaerynck, Kris Schäfer-Keller, Petra Young, James Steiger, Jürg Bock, Andreas De Geest, Sabina BMC Med Res Methodol Research Article BACKGROUND: Electronic monitoring (EM) is used increasingly to measure medication non-adherence. Unbiased EM assessment requires fulfillment of assumptions. The purpose of this study was to determine assumptions needed for internal and external validity of EM measurement. To test internal validity, we examined if (1) EM equipment functioned correctly, (2) if all EM bottle openings corresponded to actual drug intake, and (3) if EM did not influence a patient's normal adherence behavior. To assess external validity, we examined if there were indications that using EM affected the sample representativeness. METHODS: We used data from the Supporting Medication Adherence in Renal Transplantation (SMART) study, which included 250 adult renal transplant patients whose adherence to immunosuppressive drugs was measured during 3 months with the Medication Event Monitoring System (MEMS). Internal validity was determined by assessing the prevalence of nonfunctioning EM systems, the prevalence of patient-reported discrepancies between cap openings and actual intakes (using contemporaneous notes and interview at the end of the study), and by exploring whether adherence was initially uncharacteristically high and decreased over time (an indication of a possible EM intervention effect). Sample representativeness was examined by screening for differences between participants and non-participants or drop outs on non-adherence. RESULTS: Our analysis revealed that some assumptions were not fulfilled: 1) one cap malfunctioned (0.4%), 2) self-reported mismatches between bottle openings and actual drug intake occurred in 62% of the patients (n = 155), and 3) adherence decreased over the first 5 weeks of the monitoring, indicating that EM had a waning intervention effect. CONCLUSION: The validity assumptions presented in this article should be checked in future studies using EM as a measure of medication non-adherence. BioMed Central 2008-02-19 /pmc/articles/PMC2275282/ /pubmed/18284675 http://dx.doi.org/10.1186/1471-2288-8-5 Text en Copyright © 2008 Denhaerynck et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Denhaerynck, Kris
Schäfer-Keller, Petra
Young, James
Steiger, Jürg
Bock, Andreas
De Geest, Sabina
Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients
title Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients
title_full Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients
title_fullStr Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients
title_full_unstemmed Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients
title_short Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients
title_sort examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a european sample of kidney transplant patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275282/
https://www.ncbi.nlm.nih.gov/pubmed/18284675
http://dx.doi.org/10.1186/1471-2288-8-5
work_keys_str_mv AT denhaerynckkris examiningassumptionsregardingvalidelectronicmonitoringofmedicationtherapydevelopmentofavalidationframeworkanditsapplicationonaeuropeansampleofkidneytransplantpatients
AT schaferkellerpetra examiningassumptionsregardingvalidelectronicmonitoringofmedicationtherapydevelopmentofavalidationframeworkanditsapplicationonaeuropeansampleofkidneytransplantpatients
AT youngjames examiningassumptionsregardingvalidelectronicmonitoringofmedicationtherapydevelopmentofavalidationframeworkanditsapplicationonaeuropeansampleofkidneytransplantpatients
AT steigerjurg examiningassumptionsregardingvalidelectronicmonitoringofmedicationtherapydevelopmentofavalidationframeworkanditsapplicationonaeuropeansampleofkidneytransplantpatients
AT bockandreas examiningassumptionsregardingvalidelectronicmonitoringofmedicationtherapydevelopmentofavalidationframeworkanditsapplicationonaeuropeansampleofkidneytransplantpatients
AT degeestsabina examiningassumptionsregardingvalidelectronicmonitoringofmedicationtherapydevelopmentofavalidationframeworkanditsapplicationonaeuropeansampleofkidneytransplantpatients